Completed PHASE3 INTERVENTIONAL 2-arm NCT00352144

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

A Six-Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study

Sponsor: Sumitomo Pharma America, Inc.

Conditions Primary Insomnia

Interventions Eszopiclone Placebo

Updated 8 times since 2017 Last updated: Feb 21, 2012 Started: Oct 31, 2003 Primary completion: Oct 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Insomnia, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 8 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anderson, United States , Atlanta, United States , Aurora, United States , Austin, United States , Bala-Cynwyd, United States , Birmingham, United States , Blairsville, United States , Brown Deer, United States , Cary, United States and 48 more locations